Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Restless Legs Syndrome.

Suzanne Lesage1, Christopher J. Earley

  • 1Department of Neurology, Johns Hopkins Bayview Medical Center and the Johns Hopkins Center for Restless Legs Syndrome, 5501 Hopkins Bayview Circle, AAC-1B-82, Baltimore, MD 21224, USA. slesage1@jhmi.edu

Current Treatment Options in Neurology
|March 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subthalamic Nucleus Deep Brain Stimulation in Early-onset Parkinson's Disease: Clinical Outcomes in LRRK2 Mutation Carriers Compared to Non-Carriers.

Basic and clinical neuroscience·2026
Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026
Same author

Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.

NPJ Parkinson's disease·2026
Same author

Genome-wide association study of copy number variations in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Variants in the proteasome regulator PSMF1 cause a phenotypic spectrum from parkinsonism to perinatal lethality.

Nature communications·2026
Same author

Alternative Translation Initiation in PRKN Delays the Onset of Parkinson's Disease and Offers a Therapeutic Target.

Annals of neurology·2026
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Restless legs syndrome (RLS) is a common sleep disorder impacting quality of life. Treatment options include iron replacement, dopamine agonists for daily symptoms, and opiates or antiepileptics for pain, improving sleep and RLS symptom severity.

Area of Science:

  • Neurology
  • Sleep Medicine
  • Pharmacology

Background:

  • Restless Legs Syndrome (RLS) is increasingly recognized as a prevalent sleep disorder.
  • RLS significantly disrupts sleep and diminishes patients' quality of life.
  • Pharmacological interventions offer potential improvements in sleep and quality of life for RLS patients.

Purpose of the Study:

  • To review current therapeutic options for Restless Legs Syndrome.
  • To highlight the importance of evaluating and treating iron deficiency in RLS patients.
  • To discuss the efficacy and limitations of various pharmacological treatments for RLS.

Main Methods:

  • Literature review of existing studies on RLS treatment.
  • Analysis of pharmacological approaches including iron replacement, dopamine agonists, opiates, and antiepileptics.

Related Experiment Videos

  • Evaluation of treatment efficacy based on symptom relief and quality of life improvements.

    • Main Results:

    • Iron deficiency anemia should be assessed in RLS patients; iron replacement can resolve or reduce symptoms.
    • Dopamine agonists are recommended for daily RLS symptoms, with low evening doses being effective.
    • Levodopa is suitable for intermittent symptoms, while opiates and antiepileptics are beneficial for RLS with pain. Newer anticonvulsants require further clinical trials. Intravenous iron shows promise but needs further safety and dosing evaluation.

    Conclusions:

    • A multi-faceted approach to RLS treatment is essential, considering individual patient needs.
    • Iron repletion, dopamine agonists, and other agents offer viable management strategies.
    • Further research is needed for newer treatments like novel anticonvulsants and intravenous iron administration in RLS.